SCHEMBL7086543

SCHEMBL7086543

O=C(O)C1OCc2ccccc2O1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.67
POLB P06746 1/20 0.50
CASP6 P55212 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40
HSP90AB1 P08238 1/20 0.38
AKR1B1 P15121 1/20 0.36
DYRK1A Q13627 1/20 0.36
IGF1R P08069 1/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
NOTUM Q6P988 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5477951 0.86 NISCH (0.73) NISCHPOLBCASP6SMN1; SMN2HPGD
Potassium Ion SCHEMBL11364654 0.84 NISCH (0.61) NISCHPOLBCASP6SMN1; SMN2HPGD
SCHEMBL9327125 0.83 POLB (0.56) NISCHPOLBCASP6SMN1; SMN2HPGD
SCHEMBL7490172 0.82 NISCH (0.58) NISCHPOLBCASP6HPGDTSHR
Hydrochloric Acid SCHEMBL9751989 0.81 POLB (0.55) NISCHPOLBCASP6SMN1; SMN2HPGD
SCHEMBL11453649 0.79 NISCH (0.51) NISCHPOLBCASP6SMN1; SMN2HPGD
SCHEMBL7487260 0.78 NISCH (0.54) NISCHPOLBSMN1; SMN2TSHRKDM4E
SCHEMBL29606554 0.78 POLB (0.69) NISCHPOLBCASP6SMN1; SMN2HPGD
SCHEMBL2547829 0.78 POLB (0.69) NISCHPOLBCASP6SMN1; SMN2HPGD
Dimethylamine SCHEMBL9752837 0.77 POLB (0.50) NISCHPOLBCASP6SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4281012-A HYPOLIPEMIC ACTIVITY ROUSSEL UCLAF (FR) 1981-07-28 US claimed
EP-0018675-A2 Lipogenesis inhibiting composition and process for its preparation SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP claimed
EP-0018674-A1 Benzodioxincarboxylic acid derivatives, their preparation and their inclusion in lipogenesis inhibiting compositions SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP claimed
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent TOKYO OHKA KOGYO CO., LTD. (JP) 2024-01-16 US disclosed
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent TOKYO OHKA KOGYO CO., LTD. (JP) 2024-01-16 US disclosed
US-20220011665-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT TOKYO OHKA KOGYO CO., LTD. (JP) 2022-01-13 US disclosed
EP-2850070-B1 BENZO[1,3]DIOXINE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS SANOFI SA (FR) 2017-08-23 EP disclosed
US-9221784-B2 Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists SANOFI (FR) 2015-12-29 US disclosed
US-20150111889-A1 Benzo[1,3]Dioxine Derivatives And Their Use As LPAR5 Antagonists SANOFI (FR) 2015-04-23 US disclosed
EP-2850070-A1 BENZO[1,3]DIOXINE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS SANOFI (FR) 2015-03-25 EP disclosed
WO-2013171318-A1 BENZO[1,3]DIOXINE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS SANOFI (FR) 2013-11-21 WO disclosed
US-4281012-A HYPOLIPEMIC ACTIVITY ROUSSEL UCLAF (FR) 1981-07-28 US disclosed
US-4281012-A HYPOLIPEMIC ACTIVITY ROUSSEL UCLAF (FR) 1981-07-28 US disclosed
US-4281012-A HYPOLIPEMIC ACTIVITY ROUSSEL UCLAF (FR) 1981-07-28 US disclosed
EP-0018674-A1 Benzodioxincarboxylic acid derivatives, their preparation and their inclusion in lipogenesis inhibiting compositions SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP disclosed
EP-0018675-A2 Lipogenesis inhibiting composition and process for its preparation SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP disclosed
EP-0018675-A2 Lipogenesis inhibiting composition and process for its preparation SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP disclosed
EP-0018674-A1 Benzodioxincarboxylic acid derivatives, their preparation and their inclusion in lipogenesis inhibiting compositions SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP disclosed
EP-0018674-A1 Benzodioxincarboxylic acid derivatives, their preparation and their inclusion in lipogenesis inhibiting compositions SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-11-12 EP disclosed
US-4217360-A LUTEOLYTIC SCHERING AKTIENGESELLSCHAFT (DE) 1980-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111889-A1 Benzo[1,3]Dioxine Derivatives And Their Use As LPAR5 Antagonists LPAR5, LPAR1, LPAR2 NISCH 2893/4885POLB 4730/4885CASP6 3294/4885
US-20220011665-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT MRPS23, MRPS22, SLC11A2 NISCH 3746/4885POLB 1693/4885CASP6 3361/4885
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent MRPS23, MRPS22, SLC11A2 NISCH 3783/4885POLB 1789/4885CASP6 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.